Search | Clinical Trials Finder

Conditions: IgA Nephropathy, Berger Disease
Interventions: Atacicept, Placebo to match Atacicept; Biological · Other
Lead sponsor: Vera Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 428 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Brisbane, California

Conditions: Osteoarthritis, Osteoarthritis Thumb Base Joint, Carpometacarpal Osteoarthritis, Thumb
Interventions: CTM, Placebo; Device · Other
Lead sponsor: Indiana Hand to Shoulder Center; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Borderline Hypokalemia
Interventions: K+ supplement, Placebo; Drug
Lead sponsor: Duke University; Other
Eligibility: 30 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Postoperative Pain, IVF
Interventions: acetaminophen; Drug
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Manhasset, New York

Conditions: Obesity, Overweight
Interventions: Cagrilintide, Placebo (matched to Cagrilintide); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 13
States / cities: Walnut Creek, California • Fleming Island, Florida • Jacksonville, Florida + 10 more

Conditions: Respiratory Syncytial Virus (RSV)
Interventions: Low dose RSV-F Vaccine with Adjuvant, Low dose RSV-F Vaccine without Adjuvant, High dose RSV-F Vaccine with Adjuvant, High dose RSV-F Vaccine without Adjuvant, Low dose RSV-F Vaccine with Adjuvant [Bedside Mixing], Placebo; Biological
Lead sponsor: Novavax; Industry
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 330 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 4
States / cities: Anaheim, California • Rockville, Maryland • Mt. Pleasant, South Carolina + 1 more

Conditions: Allergic Rhinitis, Allergic Conjunctivitis, Atopic Dermatitis
Interventions: XmAb7195, Placebo; Biological
Lead sponsor: Xencor, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Cleft Palate
Interventions: Oral acetaminophen, Ofirmev®, Opioid only; Drug
Lead sponsor: Loma Linda University; Other
Eligibility: 5 Months to 5 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: Ulcerative Colitis
Interventions: Mirikizumab SC, Mirikizumab IV, Placebo SC; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 1,328 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 57
States / cities: Dothan, Alabama • Litchfield Park, Arizona • Phoenix, Arizona + 51 more

Conditions: Disorder Related to Lung Transplantation, Chronic Lung Allograft Dysfunction
Interventions: Pirfenidone Capsule, Placebo Capsule; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Alcohol Use Disorder
Interventions: Naltrexone; Drug
Lead sponsor: Milky Kohno; Other
Eligibility: 18 Years to 60 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: SARS-CoV-2
Interventions: mRNA-1273, Placebo; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 30,415 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 100
States / cities: Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 79 more

Conditions: Mild Traumatic Brain Injury, Post-Concussive Syndrome
Interventions: Hyperbaric Oxygen Therapy; Procedure
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 19 Years to 60 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 3
States / cities: Portsmouth, Virginia • Richmond, Virginia

Conditions: HIV Infections
Interventions: APL 400-047, ALVAC-HIV MN120TMG (vCP205), Sargramostim; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 1999
U.S. locations: 4
States / cities: Birmingham, Alabama • Baltimore, Maryland • Rochester, New York + 1 more

Conditions: Obesity
Interventions: CE-326,597, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 12
States / cities: Anniston, Alabama • Phoenix, Arizona • Anaheim, California + 8 more

Conditions: Diabetes, Type I, Diabetes, Type II, Angina, Coronary Artery Disease
Interventions: Ranolazine, Placebo; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 90 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Major Depressive Disorder
Interventions: Brexpiprazole, Antidepressant therapy; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 1,149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Hypereosinophilic Syndrome
Interventions: Mepolizumab 300 mg, Placebo matching mepolizumab, Active OCS capsules (5 mg prednisolone or prednisone), Placebo matching OCS capsules; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 7
States / cities: San Diego, California • New Haven, Connecticut • Rochester, Minnesota + 4 more

Conditions: Prostate Carcinoma
Interventions: Darolutamide, Goserelin Acetate, Leuprolide Acetate, Placebo Administration, Quality-of-Life Assessment, Triptorelin; Drug · Other
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 18 Years and older · Male only
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 115
States / cities: Duarte, California • Los Angeles, California • Palo Alto, California + 88 more

Conditions: Urticaria
Interventions: Omalizumab, Placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 40
States / cities: Granada Hills, California • Long Beach, California • Los Angeles, California + 36 more

Conditions: Intracerebral Hemorrhage
Interventions: Recombinant Factor VIIa, Biological/Vaccine: Placebo; Biological
Lead sponsor: Joseph Broderick, MD; Other
Eligibility: 18 Years to 80 Years
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 49
States / cities: Birmingham, Alabama • Baldwin Park, California • Burlingame, California + 39 more

Conditions: Barrett Esophagus, Esophageal Cancer
Interventions: acetylsalicylic acid, esomeprazole magnesium, placebo; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Autoimmune Encephalitis (AE)
Interventions: Efgartigimod PH20 (ARGX-113) SC, Placebo PH20 SC; Biological · Other
Lead sponsor: argenx; Industry
Eligibility: 12 Years and older
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2030
U.S. locations: 2
States / cities: Tucson, Arizona • Sherman, Texas

Conditions: Portal Hypertension
Interventions: Placebo, Cobiprostone; Drug
Lead sponsor: Sucampo Pharma Americas, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Dallas, Texas

Search by objective public record fields.

Atacicept in Subjects With IgA Nephropathy

Efficacy of a Single Injection of CTM for Post-Operative CMC Arthritis

The Effects of Potassium on Glucose Metabolism in African Americans

Oral Versus Intravenous Acetaminophen for Postoperative Pain Control

Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events

RSV-F Vaccine Dose Ranging Study in Young Women

Safety and Tolerability of XmAb®7195 in Adult Healthy Volunteers and Adult Subjects With a History of Allergic Rhinitis and/or Allergic Conjunctivitis and/or Atopic Dermatitis

Efficacy of Oral Versus Intravenous Acetaminophen for Primary Pediatric Cleft Palate Repair

A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis

Studying the Treatment Effect of Pirfenidone in Chronic Lung Allograft Dysfunction (STOP-CLAD)

Sex Differences in Trauma, Inflammation and Brain Function and the Implications for Treatment Efficacy in Alcohol Use Disorder

A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19

Hyperbaric Oxygen Therapy (HBO2T) for Post-Concussive Symptoms (PSC) After Mild Traumatic Brain Injury (mTBI)

A Multicenter, Randomized, Placebo-Controlled, Double-Blinded, Phase I Trial to Evaluate the Safety and Immunogenicity of Live Recombinant Canarypox ALVAC-HIV vCP205 Combined With GM-CSF in Healthy, HIV-1 Uninfected Volunteers

Study Of The Safety And Pharmacokinetics Of CE-326,597 In Patients With Asymptomatic Gallstones

Effects of Ranolazine on Coronary Flow Reserve in Symptomatic Diabetic Patients and CAD

A Trial to Evaluate the Efficacy, Safety & Tolerability of Brexpiprazole in the Maintenance Treatment of Adults With Major Depressive Disorder

Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES)

Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study

A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria

Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial - Part 2

Esomeprazole Magnesium With or Without Aspirin in Preventing Esophageal Cancer in Patients With Barrett Esophagus

A Study to Learn About How Well the Medicine Efgartigimod Works to Treat Autoimmune Encephalitis In Children 12 Years or Older and Adults

Efficacy and Safety of Cobiprostone in Patients With Portal Hypertension